Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report

• We reported the use of pazopanib in the treatment of recurrent uterine carcinosarcoma with FGFR1 amplification. • The expert tumor board recommended pazopanib for off-label use based on genetic mutations found in cancer gene panels. • Pazopanib, a multi-tyrosine kinase inhibitor, was effective aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawayama, Saki, Murakami, Ryusuke, Aki, Megumi, Kawaguchi, Yusuke, Takao, Yumi, Nonogaki, Hirofumi, Goto, Tomoyuki, Yamauchi, Chikako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108727/
https://www.ncbi.nlm.nih.gov/pubmed/35586703
http://dx.doi.org/10.1016/j.gore.2022.100993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108727/
https://www.ncbi.nlm.nih.gov/pubmed/35586703
http://dx.doi.org/10.1016/j.gore.2022.100993

Ejemplares similares